Home The Word Brain My Amedeo FAQ Privacy About   

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.

  Lung Cancer

  Free Subscription

Articles published in Mol Cancer Ther

Retrieve available abstracts of 58 articles:
HTML format

Single Articles

    May 2024
  1. XU Y, Ding K, Peng Z, Ding L, et al
    Evaluating for Correlations between Specific Metabolites in Patients Receiving First-Line or Second-Line Immunotherapy for Metastatic or Recurrent NSCLC: An Exploratory Study Based on Two Cohorts.
    Mol Cancer Ther. 2024;23:733-742.
    PubMed     Abstract available

  2. MA W, Wei S, Li Q, Zeng J, et al
    Simvastatin Overcomes Resistance to Tyrosine Kinase Inhibitors in Patient-derived, Oncogene-driven Lung Adenocarcinoma Models.
    Mol Cancer Ther. 2024;23:700-710.
    PubMed     Abstract available

    April 2024
  3. LULLA AR, Akli S, Karakas C, Caruso JA, et al
    Neutrophil Elastase Remodels Mammary Tumors to Facilitate Lung Metastasis.
    Mol Cancer Ther. 2024;23:492-506.
    PubMed     Abstract available

    March 2024
  4. MCCRURY M, Swafford K, Shuttleworth SL, Mehdi SH, et al
    Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma.
    Mol Cancer Ther. 2024;23:316-329.
    PubMed     Abstract available

    February 2024
  5. HIRAI S, Yamada T, Katayama Y, Ishida M, et al
    Effects of Combined Therapeutic Targeting of AXL and ATR on Pleural Mesothelioma Cells.
    Mol Cancer Ther. 2024;23:212-222.
    PubMed     Abstract available

    January 2024
  6. CHEN N, Tyler LC, Le AT, Welsh EA, et al
    MIG6 Mediates Adaptive and Acquired Resistance to ALK/ROS1 Fusion Kinase Inhibition through EGFR Bypass Signaling.
    Mol Cancer Ther. 2024;23:92-105.
    PubMed     Abstract available

  7. HILLEN H, Candi A, Vanderhoydonck B, Kowalczyk W, et al
    A Novel Irreversible TEAD Inhibitor, SWTX-143, Blocks Hippo Pathway Transcriptional Output and Causes Tumor Regression in Preclinical Mesothelioma Models.
    Mol Cancer Ther. 2024;23:3-13.
    PubMed     Abstract available

    December 2023
  8. GUAN C, Zhang X, Yu L
    A review of recent advances in the molecular mechanisms underlying brain metastasis in lung cancer.
    Mol Cancer Ther. 2023 Dec 20. doi: 10.1158/1535-7163.MCT-23-0416.
    PubMed     Abstract available

  9. OGIMOTO T, Ozasa H, Tsuji T, Funazo T, et al
    Combination therapy with EGFR tyrosine kinase inhibitors and TEAD inhibitor increases tumor suppression effects in EGFR mutation-positive lung cancer.
    Mol Cancer Ther. 2023 Dec 6. doi: 10.1158/1535-7163.MCT-23-0371.
    PubMed     Abstract available

  10. KHAN HY, Nagasaka M, Aboukameel A, Alkhalili O, et al
    Anticancer Efficacy of KRASG12C Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of KRASG12C-Mutant Pancreatic and Lung Cancers.
    Mol Cancer Ther. 2023;22:1422-1433.
    PubMed     Abstract available

    September 2023
  11. WENG W, Meng T, Pu J, Ma L, et al
    AMT-562, a Novel HER3-targeting Antibody-Drug Conjugate, Demonstrates a Potential to Broaden Therapeutic Opportunities for HER3-expressing Tumors.
    Mol Cancer Ther. 2023;22:1013-1027.
    PubMed     Abstract available

    August 2023
  12. HAN G, Hwang E, Lin F, Clift R, et al
    RYZ101 (Ac-225 DOTATATE) Opportunity Beyond Gastroenteropancreatic Neuroendocrine Tumors: Preclinical Efficacy in Small Cell Lung Cancer.
    Mol Cancer Ther. 2023 Aug 24:MCT-23-0029. doi: 10.1158/1535-7163.MCT-23-0029.
    PubMed     Abstract available

  13. CHERVIN AS, Stone JD, Konieczna I, Calabrese KM, et al
    ABBV-184: A Novel Survivin-specific TCR/CD3 Bispecific T-cell Engager is Active against Both Solid Tumor and Hematologic Malignancies.
    Mol Cancer Ther. 2023;22:903-912.
    PubMed     Abstract available

    July 2023
  14. LEE C, Jiang ZK, Planken S, Manzuk LK, et al
    Efficacy and Imaging-Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically Engineered Mouse Models of Cancer.
    Mol Cancer Ther. 2023;22:891-900.
    PubMed     Abstract available

  15. ALBERS J, Friese-Hamim M, Clark A, Schadt O, et al
    The Preclinical Pharmacology of Tepotinib-A Highly Selective MET Inhibitor with Activity in Tumors Harboring MET Alterations.
    Mol Cancer Ther. 2023;22:833-843.
    PubMed     Abstract available

    June 2023
  16. BUSHEY RT, Saxena R, Campa MJ, Gottlin EB, et al
    Antitumor Immune Mechanisms of the Anti-Complement Factor H Antibody GT103.
    Mol Cancer Ther. 2023;22:778-789.
    PubMed     Abstract available

    April 2023
  17. MAZAHREH R, Mason ML, Gosink JJ, Olson DJ, et al
    SGN-CD228A Is an Investigational CD228-Directed Antibody-Drug Conjugate with Potent Antitumor Activity across a Wide Spectrum of Preclinical Solid Tumor Models.
    Mol Cancer Ther. 2023;22:421-434.
    PubMed     Abstract available

    March 2023
  18. JONES RDO, Petersson K, Tabatabai A, Bao L, et al
    Pharmacokinetic/Pharmacodynamic Analysis of Savolitinib Plus Osimertinib in an EGFR-Mutation Positive, MET-Amplified Non-Small Cell Lung Cancer Model.
    Mol Cancer Ther. 2023 Mar 8:MCT-22-0193. doi: 10.1158/1535-7163.MCT-22-0193.
    PubMed     Abstract available

    February 2023
  19. MARQUES M, Corral S, Sanchez-Diaz M, Del Pozo N, et al
    Tumor and stromal cell targeting with Nintedanib and Alpelisib overcomes intrinsic bladder cancer resistance.
    Mol Cancer Ther. 2023 Feb 20:MCT-21-0667. doi: 10.1158/1535-7163.MCT-21-0667.
    PubMed     Abstract available

  20. WANG X, Raman N, Lemtiri-Chlieh G, Chang J, et al
    Griseofulvin Radiosensitizes Non-Small Cell Lung Cancer Cells and Activates cGAS.
    Mol Cancer Ther. 2023 Feb 7:MCT-22-0191. doi: 10.1158/1535-7163.MCT-22-0191.
    PubMed     Abstract available

  21. LI X, Zhou S, Abrahams CL, Krimm S, et al
    Discovery of STRO-002, a Novel Homogeneous ADC Targeting Folate Receptor Alpha, for the Treatment of Ovarian and Endometrial Cancers.
    Mol Cancer Ther. 2023;22:155-167.
    PubMed     Abstract available

    November 2022
  22. WILDEY G, Shay AM, McColl KS, Yoon S, et al
    Retinoblastoma expression and targeting by CDK4/6 inhibitors in small cell lung cancer.
    Mol Cancer Ther. 2022 Nov 18. pii: 711075. doi: 10.1158/1535-7163.MCT-22-0365.
    PubMed     Abstract available

    October 2022
  23. CROWLEY EA, Hermance NM, Herlihy CP, Manning AL, et al
    Suppression of Chromosome Instability Limits Acquired Drug Resistance.
    Mol Cancer Ther. 2022;21:1583-1593.
    PubMed     Abstract available

    September 2022
  24. CASTELLANO GM, Zeeshan S, Garbuzenko OB, Sabaawy HE, et al
    Inhibition of Mtorc1/2 and DNA-PK via CC-115 Synergizes with Carboplatin and Paclitaxel in Lung Squamous Cell Carcinoma.
    Mol Cancer Ther. 2022;21:1381-1392.
    PubMed     Abstract available

    July 2022
  25. SUN Y, Zhang Y, Schultz CW, Pommier Y, et al
    CDK7 inhibition synergizes with topoisomerase I inhibition in small cell lung cancer cells by inducing ubiquitin-mediated proteolysis of RNA polymerase II.
    Mol Cancer Ther. 2022 Jul 13. pii: 706999. doi: 10.1158/1535-7163.MCT-21-0891.
    PubMed     Abstract available

  26. DU Y, Chen Y, Wang Y, Chen J, et al
    HJM-561, a Potent, Selective, and Orally Bioavailable EGFR PROTAC that Overcomes Osimertinib-Resistant EGFR Triple Mutations.
    Mol Cancer Ther. 2022;21:1060-1066.
    PubMed     Abstract available

  27. MARTIN AL, Anadon CM, Biswas S, Mine JA, et al
    Olfactory Receptor OR2H1 Is an Effective Target for CAR T Cells in Human Epithelial Tumors.
    Mol Cancer Ther. 2022;21:1184-1194.
    PubMed     Abstract available

    June 2022
  28. WIEDEMEYER WR, Gavrilyuk J, Schammel A, Zhao X, et al
    ABBV-011, A Novel, Calicheamicin-Based Antibody-Drug Conjugate, Targets SEZ6 to Eradicate Small Cell Lung Cancer Tumors.
    Mol Cancer Ther. 2022;21:986-998.
    PubMed     Abstract available

  29. ADASHEK JJ, Menta AK, Reddy NK, Desai AP, et al
    Tissue-Agnostic Activity of BRAF plus MEK Inhibitor in BRAF V600-Mutant Tumors.
    Mol Cancer Ther. 2022;21:871-878.
    PubMed     Abstract available

  30. COKER EA, Stewart A, Ozer B, Minchom A, et al
    Individualized Prediction of Drug Response and Rational Combination Therapy in NSCLC Using Artificial Intelligence-Enabled Studies of Acute Phosphoproteomic Changes.
    Mol Cancer Ther. 2022;21:1020-1029.
    PubMed     Abstract available

    May 2022
  31. WERR L, Plenker D, Dammert MA, Lorenz C, et al
    CD74-NRG1 Fusions Are Oncogenic In Vivo and Induce Therapeutically Tractable ERBB2:ERBB3 Heterodimerization.
    Mol Cancer Ther. 2022;21:821-830.
    PubMed     Abstract available

    April 2022
  32. MIRZAPOIAZOVA T, Xiao G, Mambetsariev B, Nasser MW, et al
    Correction: Protein Phosphatase 2A as a Therapeutic Target in Small Cell Lung Cancer.
    Mol Cancer Ther. 2022;21:700.

  33. CASAZZA A, Van Helleputte L, Van Renterghem B, Pokreisz P, et al
    PhAc-ALGP-Dox, a Novel Anticancer Prodrug with Targeted Activation and Improved Therapeutic Index.
    Mol Cancer Ther. 2022;21:568-581.
    PubMed     Abstract available

  34. KENNEDY GT, Azari FS, Bernstein E, Nadeem B, et al
    A Prostate-Specific Membrane Antigen-Targeted Near-Infrared Conjugate for Identifying Pulmonary Squamous Cell Carcinoma during Resection.
    Mol Cancer Ther. 2022;21:546-554.
    PubMed     Abstract available

    January 2022
  35. JENSEN-PERGAKES K, Tatlock J, Maegley KA, McAlpine IJ, et al
    SAM-Competitive PRMT5 Inhibitor PF-06939999 Demonstrates Antitumor Activity in Splicing Dysregulated NSCLC with Decreased Liability of Drug Resistance.
    Mol Cancer Ther. 2022;21:3-15.
    PubMed     Abstract available

    December 2021
  36. JO H, Yagishita S, Hayashi Y, Ryu S, et al
    Comparative study on the efficacy and exposure of molecular target agents in non-small cell lung cancer PDX models with driver genetic alterations.
    Mol Cancer Ther. 2021 Dec 15. pii: 1535-7163.MCT-21-0371.
    PubMed     Abstract available

  37. BREHMER D, Beke L, Wu T, Millar HJ, et al
    Discovery and Pharmacological Characterization of JNJ-64619178, a Novel Small-Molecule Inhibitor of PRMT5 with Potent Antitumor Activity.
    Mol Cancer Ther. 2021;20:2317-2328.
    PubMed     Abstract available

    October 2021
  38. DASILVA JO, Yang K, Surriga O, Nittoli T, et al
    A Biparatopic Antibody-Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway Blockade.
    Mol Cancer Ther. 2021;20:1966-1976.
    PubMed     Abstract available

    September 2021
  39. YIN L, Zhang Y, Yin L, Ou Y, et al
    Novel mitochondria-based targeting restores responsiveness in therapeutically resistant human lung cancer cells.
    Mol Cancer Ther. 2021 Sep 28. pii: 1535-7163.MCT-20-1095.
    PubMed     Abstract available

  40. JUDD J, Abdel Karim N, Khan H, Naqash AR, et al
    Characterization of KRAS Mutation Subtypes in Non-Small Cell Lung Cancer.
    Mol Cancer Ther. 2021 Sep 13. pii: 1535-7163.MCT-21-0201.
    PubMed     Abstract available

  41. JIANG Y, Willmore E, Wedge SR, Ryan AJ, et al
    DNAPK Inhibition Preferentially Compromises the Repair of Radiation-induced DNA Double-strand Breaks in Chronically Hypoxic Tumor Cells in Xenograft Models.
    Mol Cancer Ther. 2021;20:1663-1671.
    PubMed     Abstract available

  42. LEI K, Kang SS, Ahn EH, Chen C, et al
    C/EBPbeta/AEP Signaling Regulates the Oxidative Stress in Malignant Cancers, Stimulating the Metastasis.
    Mol Cancer Ther. 2021;20:1640-1652.
    PubMed     Abstract available

  43. GILL SJ, Wijnhoven PWG, Fok JHL, Lloyd RL, et al
    Radiopotentiation Profiling of Multiple Inhibitors of the DNA Damage Response for Early Clinical Development.
    Mol Cancer Ther. 2021;20:1614-1626.
    PubMed     Abstract available

    August 2021
  44. LI Y, Zhang Y, Yu X, Liu Q, et al
    SAGE1: a potential target antigen for lung cancer T-cell immunotherapy.
    Mol Cancer Ther. 2021 Aug 31. pii: 1535-7163.MCT-21-0203.
    PubMed     Abstract available

  45. MERCER-SMITH AR, Jiang W, Bago JR, Valdivia A, et al
    Cytotoxic Engineered Induced Neural Stem Cells as an Intravenous Therapy for Primary Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer.
    Mol Cancer Ther. 2021 Aug 25. pii: 1535-7163.MCT-21-0109.
    PubMed     Abstract available

  46. BASCHNAGEL AM, Elnaggar JH, VanBeek HJ, Kromke AC, et al
    ATR inhibitor M6620 (VX-970) enhances the effect of radiation in non-small cell lung cancer brain metastasis patient derived xenografts.
    Mol Cancer Ther. 2021 Aug 19. pii: 1535-7163.MCT-21-0305.
    PubMed     Abstract available

  47. FUJIWARA T, Yakoub MA, Chandler A, Christ AB, et al
    CSF1/CSF1R Signaling Inhibitor Pexidartinib (PLX3397) Reprograms Tumor-Associated Macrophages and Stimulates T-cell Infiltration in the Sarcoma Microenvironment.
    Mol Cancer Ther. 2021;20:1388-1399.
    PubMed     Abstract available

  48. SURMAN DR, Xu Y, Lee MJ, Trepel J, et al
    Therapeutic Synergy in Esophageal Cancer and Mesothelioma Is Predicted by Dynamic BH3 Profiling.
    Mol Cancer Ther. 2021;20:1469-1480.
    PubMed     Abstract available

  49. JO U, Senatorov IS, Zimmermann A, Saha LK, et al
    Novel and Highly Potent ATR Inhibitor M4344 Kills Cancer Cells With Replication Stress, and Enhances the Chemotherapeutic Activity of Widely Used DNA Damaging Agents.
    Mol Cancer Ther. 2021;20:1431-1441.
    PubMed     Abstract available

  50. SMITH RA, Zammit DJ, Damle NK, Usansky H, et al
    ASN004, A 5T4-targeting scFv-Fc Antibody-Drug Conjugate with High Drug-to-Antibody Ratio, Induces Complete and Durable Tumor Regressions in Preclinical Models.
    Mol Cancer Ther. 2021;20:1327-1337.
    PubMed     Abstract available

    July 2021
  51. MIRZAPOIAZOVA T, Xiao G, Mambetsariev B, Nasser MW, et al
    Protein phosphatase 2A as a therapeutic target in small cell lung cancer.
    Mol Cancer Ther. 2021 Jul 12. pii: 1535-7163.MCT-21-0013.
    PubMed     Abstract available

    June 2021
  52. ZHANG D, Hou Z, Aldrich KE, Lockwood L, et al
    A novel Nrf2 pathway inhibitor sensitizes Keap1-mutant lung cancer cells to chemotherapy.
    Mol Cancer Ther. 2021 Jun 22. pii: 1535-7163.MCT-21-0210.
    PubMed     Abstract available

  53. KANO H, Ichihara E, Watanabe H, Nishii K, et al
    SHP2 inhibition enhances the effects of tyrosine kinase inhibitors in preclinical models of treatment-naive ALK-, ROS1-, or EGFR-altered non-small-cell lung cancer.
    Mol Cancer Ther. 2021 Jun 22. pii: 1535-7163.MCT-20-0965.
    PubMed     Abstract available

  54. TANG TT, Konradi AW, Feng Y, Peng X, et al
    Small Molecule Inhibitors of TEAD Auto-palmitoylation Selectively Inhibit Proliferation and Tumor Growth of NF2-deficient Mesothelioma.
    Mol Cancer Ther. 2021;20:986-998.
    PubMed     Abstract available

    May 2021
  55. SUN D, Nikonova AS, Zhang P, Deneka AY, et al
    Evaluation of the small-molecule BRD4-degrader CFT-2718 in small cell lung cancer and pancreatic cancer models.
    Mol Cancer Ther. 2021 May 27. pii: 1535-7163.MCT-20-0831.
    PubMed     Abstract available

    May 2020
  56. ZENKE FT, Zimmermann A, Sirrenberg C, Dahmen H, et al
    Pharmacologic Inhibitor of DNA-PK, M3814, Potentiates Radiotherapy and Regresses Human Tumors in Mouse Models.
    Mol Cancer Ther. 2020;19:1091-1101.
    PubMed     Abstract available

  57. YAMASHITA D, Minata M, Ibrahim AN, Yamaguchi S, et al
    Identification of ALDH1A3 as a Viable Therapeutic Target in Breast Cancer Metastasis-Initiating Cells.
    Mol Cancer Ther. 2020;19:1134-1147.
    PubMed     Abstract available

    April 2020
  58. KOTANIDES H, Sattler RM, Lebron MB, Carpenito C, et al
    Characterization of 7A5: A Human CD137 (4-1BB) Receptor Binding Monoclonal Antibody with Differential Agonist Properties That Promotes Antitumor Immunity.
    Mol Cancer Ther. 2020;19:988-998.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.